Published in J Clin Oncol on July 01, 2008
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol (2015) 5.48
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A (2009) 3.19
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol (2009) 3.14
Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol (2011) 2.76
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol (2014) 2.75
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer (2011) 2.19
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol (2015) 2.12
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer (2011) 1.95
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol (2009) 1.84
Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol (2010) 1.83
ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics (2012) 1.74
Cancer. Circulating tumor cells. Science (2013) 1.68
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol (2010) 1.66
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res (2010) 1.65
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
Microchip-based immunomagnetic detection of circulating tumor cells. Lab Chip (2011) 1.59
Detecting circulating tumor cells: current challenges and new trends. Theranostics (2013) 1.55
Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Front Oncol (2012) 1.54
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer (2013) 1.51
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol (2012) 1.44
Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget (2011) 1.43
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology (2015) 1.42
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer (2011) 1.39
A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res (2010) 1.37
Circulating tumor cells: from bench to bedside. Annu Rev Med (2012) 1.29
Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol (2010) 1.29
Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget (2013) 1.27
Microfluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis. Anal Chem (2012) 1.26
Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient. Front Oncol (2012) 1.26
Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol (2009) 1.26
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.23
Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep (2010) 1.21
Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med (2014) 1.18
Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther (2013) 1.15
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med (2011) 1.15
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One (2014) 1.14
Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res (2011) 1.13
Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems. Biomicrofluidics (2013) 1.12
Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res (2012) 1.12
mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One (2012) 1.12
Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics (2011) 1.11
MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest (2014) 1.09
Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One (2015) 1.08
γ-H2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta (2012) 1.07
Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS One (2013) 1.06
Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology (2011) 1.06
NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods (2013) 1.05
Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med (2013) 1.05
Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol (2010) 1.05
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta (2009) 1.03
The systematic study of circulating tumor cell isolation using lithographic microfilters. RSC Adv (2015) 1.03
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One (2011) 1.03
Circulating tumor cells, enumeration and beyond. Cancers (Basel) (2010) 1.03
Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer (2012) 1.02
Nanoparticles and their applications in cell and molecular biology. Integr Biol (Camb) (2014) 1.02
Squamous cell carcinoma of the oral cavity and circulating tumour cells. World J Clin Oncol (2014) 1.02
The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep (2015) 1.02
Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta (2012) 1.02
Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin Cancer Res (2010) 1.01
Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01
Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg (2012) 1.01
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer (2015) 1.00
Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One (2010) 1.00
Emerging role of nanomaterials in circulating tumor cell isolation and analysis. ACS Nano (2014) 1.00
Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol (2011) 0.99
Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med (2012) 0.98
High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer (2015) 0.96
Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One (2014) 0.96
The promise of circulating tumor cell analysis in cancer management. Genome Biol (2014) 0.95
Filtration parameters influencing circulating tumor cell enrichment from whole blood. PLoS One (2013) 0.94
Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. Biomed Res Int (2014) 0.94
Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol (2012) 0.94
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer (2013) 0.94
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med (2014) 0.94
Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget (2014) 0.94
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev (2014) 0.94
Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther (2015) 0.93
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol (2007) 7.67
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol (2007) 4.06
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 3.85
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol (2005) 3.44
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol (2006) 3.31
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol (2009) 3.14
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife (2013) 2.66
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg (2008) 2.40
Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc (2003) 2.32
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology (2013) 2.17
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology (2005) 2.15
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol (2011) 2.06
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol (2010) 2.05
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer (2009) 1.94
The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2003) 1.93
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer (2010) 1.84
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res (2007) 1.84
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol (2002) 1.84